• *IL=interleukin.
    In VOYAGE 1, 837 patients were randomized to placebo (n=174), TREMFYATM 100 mg every 8 weeks (q8w) after Weeks 0 and 4 (n=329), or Humira® (adalimumab) 80 mg at Week 0, 40 mg at Week 1, and 40 mg every 2 weeks thereafter (n=334). Eligible patients (≥18 years of age) had moderate to severe plaque psoriasis (ie, Investigator Global Assessment [IGA] score ≥3, Psoriasis Area and Severity Index [PASI] score ≥12, body surface area [BSA] involvement ≥10%) for at least 6 months and were candidates for systemic therapy or phototherapy. The study comprised a placebo-controlled period (Weeks 0 to 16) after which patients taking placebo crossed over to receive TREMFYATM at Week 16 and 20 and q8w thereafter through Week 48 and an active-comparator–controlled period when TREMFYATM was compared with Humira® from Week 0 through Week 48.1 Please see complete Study Design.
    TREMFYATM (guselkumab) is a trademark of Janssen Biotech, Inc. Humira® (adalimumab) is a registered trademark of AbbVie Inc.

REGISTER FOR UPDATES

Complete the registration form below to receive the latest materials about TREMFYA™ as well as important information to support the treatment of your patients.

The information you provide will only be used by Janssen Biotech, Inc., our affiliates, and our service providers to send you information about TREMFYA™ and to fulfill any optional requests you may indicate. You may unsubscribe here or by following the instructions in the messages you receive. Our Privacy Policy governs the use of the information you provide. By providing the information and selecting the “Submit” button, you indicate you read, understand, and agree to these terms.

All fields required.